Autonomix Medical, Inc. Announces Abstract Highlighting Preliminary Positive Clinical Results Accepted at The Society of Interventional Oncology (SIO) 2025 Annual Scientific Meeting
Autonomix Medical (NASDAQ: AMIX) announced the acceptance of its abstract for poster presentation at the Society of Interventional Oncology (SIO) 2025 Annual Scientific Meeting, scheduled for January 30 – February 3, 2025, in Las Vegas. The abstract, titled 'Ablation of the Celiac Ganglia for Treatment of Pancreatic Cancer Pain: An Interim Analysis of the First Five Lead-In Patients,' will be presented by the company's Chief Medical Officer, Dr. Rob Schwartz.
The presentation at SIO, a non-profit organization focused on advancing interventional oncology as a key cancer therapy approach, represents an opportunity to showcase the company's progress in developing treatments for diseases involving the nervous system.
Autonomix Medical (NASDAQ: AMIX) ha annunciato l'accettazione del suo abstract per la presentazione in poster alla Società di Oncologia Interventistica (SIO) 2025 Annual Scientific Meeting, prevista per il 30 gennaio – 3 febbraio 2025, a Las Vegas. L'abstract, intitolato 'Ablazione dei gangli celiaci per il trattamento del dolore del cancro pancreatico: un'analisi intermedia dei primi cinque pazienti di prova,' sarà presentato dal Chief Medical Officer dell'azienda, il dott. Rob Schwartz.
La presentazione alla SIO, un'organizzazione no-profit focalizzata sull'avanzamento dell'oncologia interventistica come approccio chiave alla terapia oncologica, rappresenta un'opportunità per mettere in mostra i progressi dell'azienda nello sviluppo di trattamenti per malattie che coinvolgono il sistema nervoso.
Autonomix Medical (NASDAQ: AMIX) anunció la aceptación de su resumen para la presentación en póster en el Encuentro Científico Anual de la Sociedad de Oncología Intervencionista (SIO) 2025, programado del 30 de enero al 3 de febrero de 2025 en Las Vegas. El resumen, titulado 'Ablación de los ganglios celiacos para el tratamiento del dolor del cáncer de páncreas: un análisis intermedio de los primeros cinco pacientes de prueba,' será presentado por el Director Médico de la compañía, el Dr. Rob Schwartz.
La presentación en SIO, una organización sin fines de lucro centrada en avanzar en la oncología intervencionista como un enfoque clave de terapia contra el cáncer, representa una oportunidad para mostrar los progresos de la compañía en el desarrollo de tratamientos para enfermedades que afectan el sistema nervioso.
Autonomix Medical (NASDAQ: AMIX)는 2025년 제약학회(SIO) 연례 과학 회의에서 포스터 발표를 위한 초록이 수락되었음을 발표했습니다. 이 회의는 2025년 1월 30일부터 2월 3일까지 라스베이거스에서 개최됩니다. 초록의 제목은 '췌장암 통증 치료를 위한 배꼽신경절 절개: 첫 5명의 선도 환자에 대한 중간 분석'이며, 회사의 최고 의료 책임자인 로브 슈워츠 박사가 발표할 예정입니다.
SIO에서의 발표는 암 치료 접근법의 핵심으로써 중재적 온콜로지를 발전시키는 데 초점을 맞춘 비영리 단체인 SIO에서 회사의 신경계 질환 치료 개발에 대한 진전을 선보일 수 있는 기회를 제공합니다.
Autonomix Medical (NASDAQ: AMIX) a annoncé l'acceptation de son résumé pour une présentation par affichage lors de la Société d'Oncologie Interventionnelle (SIO) 2025 Annual Scientific Meeting, prévue du 30 janvier au 3 février 2025 à Las Vegas. Le résumé, intitulé 'Ablation des ganglions cœliaques pour traiter la douleur liée au cancer du pancréas : une analyse intermédiaire des cinq premiers patients,', sera présenté par le Directeur Médical de l'entreprise, le Dr Rob Schwartz.
La présentation à la SIO, une organisation à but non lucratif axée sur l'avancement de l'oncologie interventionnelle en tant qu'approche clé du traitement du cancer, représente une opportunité de mettre en avant les progrès réalisés par l'entreprise dans le développement de traitements pour les maladies affectant le système nerveux.
Autonomix Medical (NASDAQ: AMIX) gab die Annahme seines Abstracts für die Posterpräsentation bei der Gesellschaft für Interventionelle Onkologie (SIO) 2025 Jahrestagung bekannt, die vom 30. Januar bis 3. Februar 2025 in Las Vegas stattfinden wird. Das Abstract mit dem Titel 'Ablation der celiac Ganglien zur Behandlung von Schmerzen bei Bauchspeicheldrüsenkrebs: eine Zwischenanalyse der ersten fünf Patienten,' wird von dem Chief Medical Officer des Unternehmens, Dr. Rob Schwartz, präsentiert.
Die Präsentation bei der SIO, einer gemeinnützigen Organisation, die sich auf die Förderung der interventionellen Onkologie als wichtigen Ansatz in der Krebsbehandlung konzentriert, stellt eine Möglichkeit dar, den Fortschritt des Unternehmens bei der Entwicklung von Therapien für Erkrankungen des Nervensystems zu zeigen.
- Abstract acceptance at major scientific meeting indicates preliminary clinical progress
- First clinical data presentation for lead-in patients in pancreatic cancer pain treatment
- None.
Insights
Autonomix Medical's abstract acceptance at SIO 2025 focuses on celiac ganglia ablation for pancreatic cancer pain management, representing a targeted approach in interventional pain management. While the abstract acceptance itself is a standard academic milestone, this is categorized as not impactful news for several key reasons:
1. This is a preliminary analysis of only five "lead-in" patients, which is too small a sample size to draw meaningful conclusions or impact market dynamics.
2. The presentation is at a future conference and while SIO is a respected organization, conference presentations typically don't materially affect stock performance unless they reveal significant new data.
3. No specific clinical outcomes or data points are provided in the announcement that could influence investment decisions.
4. This type of news, while important for academic and professional networking, falls under routine operational updates rather than market-moving developments like FDA approvals, significant trial results, or financial updates.
THE WOODLANDS, TX, Jan. 13, 2025 (GLOBE NEWSWIRE) -- Autonomix Medical, Inc. (NASDAQ: AMIX) (“Autonomix” or the “Company”), a medical device company focused on advancing innovative technologies to revolutionize how diseases involving the nervous system are diagnosed and treated, today announced its abstract has been accepted for poster presentation at the SIO 2025 Annual Scientific Meeting, being held January 30 – February 3, 2025 in Las Vegas, NV.
Details of the accepted abstract are as follows:
Title: Ablation of the Celiac Ganglia for Treatment of Pancreatic Cancer Pain: An Interim Analysis of the First Five “Lead-In” Patients
Author: Rob Schwartz, M.D., Chief Medical Officer of Autonomix
SIO is a non-profit organization dedicated to promoting and supporting the field of interventional oncology (IO), aiming to establish it as a key pillar of cancer therapy alongside medical, surgical, and radiation oncology; providing a community for healthcare professionals to connect, share knowledge, advocate for IO advancements, and improve patient access to these minimally invasive cancer treatments through education and research initiatives.
For more information about the 2025 SIO Annual Meeting, please visit the meeting website.
About Autonomix Medical, Inc.
Autonomix is a medical device company focused on advancing innovative technologies to revolutionize how diseases involving the nervous system are diagnosed and treated. The Company’s first-in-class platform system technology includes a catheter-based microchip sensing array that may have the ability to detect and differentiate neural signals with approximately 3,000 times greater sensitivity than currently available technologies. We believe this will enable, for the first time ever, transvascular diagnosis and treatment of diseases involving the peripheral nervous system virtually anywhere in the body.
We are initially developing this technology for the treatment of pain, with initial trials focused on pancreatic cancer, a condition that causes debilitating pain and is without a reliable solution. Our technology constitutes a platform to address dozens of potential indications, including cardiology, hypertension and chronic pain management, across a wide disease spectrum. Our technology is investigational and has not yet been cleared for marketing in the United States.
For more information, visit autonomix.com and connect with the Company on X, LinkedIn, Instagram and Facebook.
Forward Looking Statements
Some of the statements in this release are “forward-looking statements,” which involve risks and uncertainties. Forward-looking statements in this press release include, without limitation, the potential of the technology to treat cancerous tumors and the pain associated with pancreatic cancer. Such forward-looking statements can be identified by the use of words such as “should,” “might,” “may,” “intends,” “anticipates,” “believes,” “estimates,” “projects,” “forecasts,” “expects,” “plans,” and “proposes.”
Although Autonomix believes that the expectations reflected in these forward-looking statements are based on reasonable assumptions, there are a number of risks and uncertainties that could cause actual results to differ materially from such forward-looking statements. You are urged to carefully review and consider any cautionary statements and other disclosures, including the statements made under the heading “Risk Factors” and elsewhere in the Annual Report on Form 10-K filed with the U.S. Securities and Exchange Commission (SEC) on May 31, 2024. Forward-looking statements speak only as of the date of the document in which they are contained and Autonomix does not undertake any duty to update any forward-looking statements except as may be required by law.
Investor and Media Contact
JTC Team, LLC
Jenene Thomas
908.824.0775
autonomix@jtcir.com
FAQ
What is the focus of Autonomix Medical's (AMIX) abstract presentation at SIO 2025?
When and where will Autonomix Medical (AMIX) present their clinical results at SIO 2025?
Who will present Autonomix Medical's (AMIX) clinical results at SIO 2025?
What type of treatment is Autonomix Medical (AMIX) developing for pancreatic cancer patients?
